Edesa Biotech Reports Fiscal Year 2025 Results
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year end
(Financial Post, 2025-12-12T21:21:58Z)